ES2184310T3 - Formulacion autoemulsionante para compuestos lipofilos acidos. - Google Patents

Formulacion autoemulsionante para compuestos lipofilos acidos.

Info

Publication number
ES2184310T3
ES2184310T3 ES98936888T ES98936888T ES2184310T3 ES 2184310 T3 ES2184310 T3 ES 2184310T3 ES 98936888 T ES98936888 T ES 98936888T ES 98936888 T ES98936888 T ES 98936888T ES 2184310 T3 ES2184310 T3 ES 2184310T3
Authority
ES
Spain
Prior art keywords
self
pharmaceutically acceptable
formulation
lipofil
emulsioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98936888T
Other languages
English (en)
Inventor
Walter Morozowich
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2184310T3 publication Critical patent/ES2184310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

La presente invención se refiere a una nueva composición farmacéutica basada en la utilización de una cierta cantidad de una amina básica, conteniendo esta composición un compuesto de piranona como agente farmacéuticamente activo; una cantidad de amina básica que varía aproximadamente entre 0,1 y 10% en peso de la composición total, uno o varios solventes farmacéuticamente aceptables; y uno o varios tensioactivos farmacéuticamente aceptables. Esta composición, que puede contener además uno o varios aceites farmacéuticamente aceptables; se presenta en forma de una formulación autoemulsionante que presenta una concentración elevada de compuestos de piranona lipofílicas y una biodisponibilidad oral importante para estos últimos.
ES98936888T 1997-07-29 1998-07-27 Formulacion autoemulsionante para compuestos lipofilos acidos. Expired - Lifetime ES2184310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ES2184310T3 true ES2184310T3 (es) 2003-04-01

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98936888T Expired - Lifetime ES2184310T3 (es) 1997-07-29 1998-07-27 Formulacion autoemulsionante para compuestos lipofilos acidos.

Country Status (25)

Country Link
US (1) US6231887B1 (es)
EP (1) EP0989851B1 (es)
JP (1) JP4524367B2 (es)
KR (1) KR100509131B1 (es)
CN (1) CN1112927C (es)
AT (1) ATE225174T1 (es)
AU (1) AU728626B2 (es)
BR (1) BR9810729B1 (es)
CA (1) CA2294033C (es)
CY (1) CY2006002I2 (es)
CZ (1) CZ296957B6 (es)
DE (1) DE69808463T2 (es)
DK (1) DK0989851T3 (es)
ES (1) ES2184310T3 (es)
FI (1) FI20000172A (es)
HK (1) HK1028879A1 (es)
HU (1) HU228923B1 (es)
NO (1) NO323425B1 (es)
NZ (1) NZ502566A (es)
PL (1) PL192865B1 (es)
PT (1) PT989851E (es)
RU (1) RU2202346C2 (es)
SI (1) SI0989851T1 (es)
SK (1) SK284616B6 (es)
WO (1) WO1999006044A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
WO2000057885A1 (en) * 1999-03-31 2000-10-05 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4298998B2 (ja) 2000-10-31 2009-07-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ピラノンプロテアーゼインヒビターの経口投与自己乳化製剤
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
UA81028C2 (en) * 2003-04-02 2007-11-26 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis c viral protease inhibitors
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CA2541398C (en) * 2003-10-07 2012-08-21 Eli Lilly And Company Liquid formulations of ractopamine
WO2006055754A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
CA2586501A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
CA2767692C (en) 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
RU2419426C1 (ru) 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
AP3552A (en) 2010-05-03 2016-01-18 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
BR112015015864B1 (pt) * 2013-01-14 2022-08-23 Infirst Healthcare Limited Uso de uma composição farmacêutica no tratamento de uma condição de dor severa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH10504291A (ja) * 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
TR199701541T1 (xx) 1995-06-06 1998-03-21 F.Hoffmann-La Roche Ag Proteinaz engelleyici ve tekli gliserid i�eren farmas�tik bile�im.
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
CY2006002I1 (el) 2011-02-02
PL338335A1 (en) 2000-10-23
SK162000A3 (en) 2000-12-11
NO20000466L (no) 2000-03-28
CZ296957B6 (cs) 2006-08-16
JP2002510330A (ja) 2002-04-02
WO1999006044A1 (en) 1999-02-11
CN1261796A (zh) 2000-08-02
KR100509131B1 (ko) 2005-08-18
AU728626B2 (en) 2001-01-11
AU8573898A (en) 1999-02-22
HUP0002440A3 (en) 2001-10-29
CA2294033C (en) 2007-01-09
CZ2000156A3 (cs) 2000-05-17
ATE225174T1 (de) 2002-10-15
PL192865B1 (pl) 2006-12-29
FI20000172A (fi) 2000-01-28
NO323425B1 (no) 2007-04-30
DE69808463D1 (de) 2002-11-07
JP4524367B2 (ja) 2010-08-18
BR9810729B1 (pt) 2010-07-13
CN1112927C (zh) 2003-07-02
CY2006002I2 (el) 2012-01-25
DK0989851T3 (da) 2003-01-27
CA2294033A1 (en) 1999-02-11
HUP0002440A2 (hu) 2001-09-28
US6231887B1 (en) 2001-05-15
EP0989851A1 (en) 2000-04-05
DE69808463T2 (de) 2003-06-26
HU228923B1 (en) 2013-06-28
NZ502566A (en) 2002-03-28
RU2202346C2 (ru) 2003-04-20
BR9810729A (pt) 2000-08-08
EP0989851B1 (en) 2002-10-02
KR20010022369A (ko) 2001-03-15
SK284616B6 (sk) 2005-07-01
PT989851E (pt) 2002-12-31
HK1028879A1 (en) 2001-03-09
SI0989851T1 (en) 2003-04-30
NO20000466D0 (no) 2000-01-28

Similar Documents

Publication Publication Date Title
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
UY27320A1 (es) Nuevas composiciones farmacéuticas
IL179718A0 (en) Pharmaceutical composition containing irbesartan
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
UY29905A1 (es) Formulación farmacéutica de absorción oral y su método de administración
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
TW200517106A (en) Sustained release pharmaceutical compositions
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
ECSP088732A (es) Aerosoles dosificadores para la administración de preparaciones farmacéuticas
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
DK0853476T5 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
CR6513A (es) Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas
DE60017720D1 (de) Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
PE20011092A1 (es) Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
PE20011099A1 (es) Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene oxidacion reducida